Apollomics Posts $8.8M H1 Loss With Just $1.0M Cash on Hand
APLM sits 82% above its 52-week low of $10.006.
Summary
Apollomics reported a first-half 2026 net loss of $8.8 million, or $4.06 per share, narrower than the $12.5 million loss a year earlier, but the balance sheet is the story. Cash and equivalents stood at $1.0 million on June 30, 2026, down from $3.3 million at year-end 2025, and the company had no revenue versus $8.5 million in the prior-year period. Cost cuts drove the improvement: R&D fell to $2.0 million from $4.6 million and G&A dropped to $4.5 million from $14.5 million. The company also booked a $2.3 million expected credit loss impairment on financial assets. This follows the 6-K filed November 6 that disclosed the going-concern warning; the roughly $10.0 million private placement signed in August is the only near-term funding cushion, and insiders including the CEO and CFO bought into it at $15.00 per share.
At the time of this announcement, APLM was trading at $18.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.2M. The 52-week trading range was $10.01 to $28.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.